Fig. 3

Cardiac magnetic resonance imaging (MRI) after six days of gilteritinib targeted therapy. After gilteritinib initiation, the patient developed significant clinical heart failure. Cardiac MRI revealed new left ventricular dilation and depressed systolic function with evidence of myocardial edema/ inflammation on T2 mapping (red arrows; max T2 of 70 milliseconds, normal < 53 ms), as well as patchy correlating non-ischemic patterned fibrosis with late gadolinium enhancement (LGE). Myocardial extracellular volume fraction was also elevated (not shown here). However, five months after therapeutic cessation, systolic function normalized with injury resolution (green arrows)